RealTime Dynamix™: Multiple Sclerosis EU Q3 2018 Spotlight

RealTime Dynamix™: Multiple Sclerosis EU Q3 2018 Spotlight

Real time dynamix

Driven by the availability of Merck KGaA’s Mavenclad and substantial uptake of Biogen’s Tecfidera, the oral disease-modifying therapy (DMT) class share of DMT-treated multiple sclerosis (MS) patients increased significantly in the EU over the past six months, putting significant pressure on Teva’s Copaxone. See complimentary highlights from our bi-annual tracker of the EU MS market, RealTime Dynamix™: Multiple Sclerosis EU.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the EU report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.

2018-10-12T12:52:10+00:00